Pharma’s India–China Dependence
What happened
Analysts note Europe’s pharmaceutical industry is increasingly dependent on India and China for key inputs — GMP intermediates, regulated starting materials and active pharmaceutical ingredients. (x.com) That concentration raises sourcing and regulatory risk for European manufacturers and opens up strategic choices around onshoring, dual‑sourcing and inventory policy.
Why it matters
An EU advisory opinion and recent industry analyses quantify the concentration: up to 80% of the active ingredients used in European medicines and roughly 40% of finished drugs come from India or China, according to the European Economic and Social Committee. (eesc.europa.eu) A concrete sign of fragility came in March 2024 when EuroAPI paused production at its Brindisi plant after internal quality-control findings halted output of 11 ingredients and intermediates, a disruption that the company said would hit its 2024 guidance and form part of a wider footprint rationalization. (euroapi.com) Those European shortages sit in a global web: India—Europe’s largest generic-drug supplier—relies heavily on Chinese imports for raw materials, with China accounting for about 43.45% of India’s pharmaceutical imports in 2023–24, which means supply shocks in one country can cascade through multiple manufacturing hubs. (policycircle.org) The technical pieces that are concentrated are: "active pharmaceutical ingredients" (the single chemical in a pill that produces the therapeutic effect), "regulated starting materials" (chemical inputs that enter the validated manufacturing process and are controlled by regulators), and "GMP intermediates" (partially processed materials made under Good Manufacturing Practice quality rules but not yet final ingredients). (europarl.europa.eu) Those trends have measurable scale and cost consequences: Europe’s share of API entries in regulatory files fell from roughly 42% in 2000 to about 10% in 2023, rebuilding a single active-substance production line can cost an estimated €50–180 million and take 3–6 years, and independent analyses estimate Europe’s medicines value chain is more than 74% import‑dependent. (pharmtech.com) (eesc.europa.eu) (efcg.cefic.org) Policy responses and commercial tactics now on the table are specific: the European Commission has discussed a "Critical Medicines" framework and Parliament held a public hearing on boosting on‑shore API and finished‑medicine production on 29 January 2025, proposals that include targeted investment, the power to require strategic stockpiles, and incentives for local manufacturing; commercial mitigations being deployed by buyers include formal dual‑sourcing clauses, larger safety inventories, and deeper CDMO (contract development and manufacturing organization) partnerships to spread regulatory and quality risk. (pharmaceutical-technology.com) (pharmtech.com)
Key numbers
- An EU advisory opinion and recent industry analyses quantify the concentration: up to 80% of the active ingredients used in European medicines and roughly 40% of finished drugs come from India or China, according to the European Economic and Social Committee.
Quick answers
What happened in Pharma’s India–China Dependence?
Analysts note Europe’s pharmaceutical industry is increasingly dependent on India and China for key inputs — GMP intermediates, regulated starting materials and active pharmaceutical ingredients. (x.com) That concentration raises sourcing and regulatory risk for European manufacturers and opens up strategic choices around onshoring, dual‑sourcing and inventory policy.
Why does Pharma’s India–China Dependence matter?
An EU advisory opinion and recent industry analyses quantify the concentration: up to 80% of the active ingredients used in European medicines and roughly 40% of finished drugs come from India or China, according to the European Economic and Social Committee. (eesc.europa.eu) A concrete sign of fragility came in March 2024 when EuroAPI paused production at its Brindisi plant after internal quality-control findings halted output of 11 ingredients and intermediates, a disruption that the company said would hit its 2024 guidance and form part of a wider footprint rationalization. (euroapi.com) Those European shortages sit in a global web: India—Europe’s largest generic-drug supplier—relies heavily on Chinese imports for raw materials, with China accounting for about 43.45% of India’s pharmaceutical imports in 2023–24, which means supply shocks in one country can cascade through multiple manufacturing hubs. (policycircle.org) The technical pieces that are concentrated are: "active pharmaceutical ingredients" (the single chemical in a pill that produces the therapeutic effect), "regulated starting materials" (chemical inputs that enter the validated manufacturing process and are controlled by regulators), and "GMP intermediates" (partially processed materials made under Good Manufacturing Practice quality rules but not yet final ingredients). (europarl.europa.eu) Those trends have measurable scale and cost consequences: Europe’s share of API entries in regulatory files fell from roughly 42% in 2000 to about 10% in 2023, rebuilding a single active-substance production line can cost an estimated €50–180 million and take 3–6 years, and independent analyses estimate Europe’s medicines value chain is more than 74% import‑dependent. (pharmtech.com) (eesc.europa.eu) (efcg.cefic.org) Policy responses and commercial tactics now on the table are specific: the European Commission has discussed a "Critical Medicines" framework and Parliament held a public hearing on boosting on‑shore API and finished‑medicine production on 29 January 2025, proposals that include targeted investment, the power to require strategic stockpiles, and incentives for local manufacturing; commercial mitigations being deployed by buyers include formal dual‑sourcing clauses, larger safety inventories, and deeper CDMO (contract development and manufacturing organization) partnerships to spread regulatory and quality risk. (pharmaceutical-technology.com) (pharmtech.com)
